Table 7.
Cox proportional hazard modelling of UBE2O after accounting for overall survival—173 from 335 patients with prostate cancer could be evaluated for survival.
| Univariate | Multivariate | |||||||
|---|---|---|---|---|---|---|---|---|
| HR | Lower | Upper | p-Value | HR | Lower | Upper | p-Value | |
| Height | 0.980 | 0.931 | 1.031 | 0.434 | ||||
| Weight | 0.973 | 0.939 | 1.009 | 0.139 | ||||
| Age | 1.032 | 0.981 | 1.087 | 0.225 | 1.052 | 0.99 | 1.117 | 0.102 |
| Adjuvant treatment: no | Reference | Reference | ||||||
| Adjuvant treatment: yes | 0.733 | 0.379 | 1.417 | 0.356 | 0.399 | 0.174 | 0.915 | 0.030 |
| UBE2O grade 1 | Reference | Reference | ||||||
| UBE2O grade 2 | 0.776 | 0.320 | 1.883 | 0.575 | 0.503 | 0.197 | 1.289 | 0.152 |
| UBE2O grade 3 | 0.473 | 0.182 | 1.230 | 0.125 | 0.310 | 0.112 | 0.856 | 0.024 |
| PSA grade 0 | Reference | |||||||
| PSA grade 1 | 1.332 | 0.633 | 2.805 | 0.451 | ||||
| PSA grade 2 | 1.573 | 0.748 | 3.309 | 0.233 | ||||
| Gleason score grade 0 | Reference | |||||||
| Gleason score grade 1 | 0.869 | 0.349 | 2.159 | 0.762 | ||||
| Gleason score grade 2 | 0.707 | 0.298 | 1.678 | 0.431 | ||||
| Pathologic T stage grade 0 | Reference | Reference | ||||||
| Pathologic T stage grade 1 | 1.818 | 0.981 | 3.370 | 0.058 | 2.458 | 1.155 | 5.232 | 0.020 |
| Seminal vesicle invasion: negative | Reference | |||||||
| Seminal vesicle invasion: positive | 1.915 | 0.954 | 3.843 | 0.067 | ||||
| Regional lymph node: negative | Reference | |||||||
| Regional lymph node: positive | 2.098 | 0.817 | 5.386 | 0.123 | ||||
| Surgical margin: negative | Reference | |||||||
| Surgical margin: positive | 1.183 | 0.638 | 2.191 | 0.594 | ||||
UBE2O grade—0: negative, 1: weak, 2: moderate, 3: strong. PSA grade 0: PSA < 10 ng/mL, 1: PSA 10–20 ng/mL, 2: PSA > 20 ng/mL. Gleason score grade—0: Gleason score ≤ 6, 1: Gleason score 7, 2: Gleason score ≥ 8. Pathologic T stage grade—0: ≤T2, 1: ≥T3.